TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
Immunomodulation
Immunotherapy
Immunotherapy, Adoptive
T-Lymphocytes
Transplantation Immunology
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
accepted:
01
03
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
9
4
2022
Statut:
ppublish
Résumé
Targeting immune checkpoints that inhibit antitumor immune responses has emerged as a powerful new approach to treat cancer. We recently showed that blocking the tumor necrosis factor receptor-type 2 (TNFR2) pathway induces the complete loss of the protective function of regulatory T cells (Tregs) in a model of graft-versus-host disease (GVHD) prevention that relies on Treg-based cell therapy. Here, we tested the possibility of amplifying the antitumor response by targeting TNFR2 in a model of tumor relapse following hematopoietic stem-cell transplantation, a clinical situation for which the need for efficient therapeutic options is still unmet. We developed appropriate experimental conditions that mimic patients that relapsed from their initial hematological malignancy after hematopoietic stem-cell transplantation. This consisted of defining in allogeneic bone marrow transplantation models developed in mice, the maximum number of required tumor cells and T cells to infuse into recipient mice to develop a model of tumor relapse without inducing GVHD. We next evaluated whether anti-TNFR2 treatment could trigger alloreactivity and consequently antitumor immune response. In parallel, we also studied the differential expression of TNFR2 on T cells including Treg from patients in post-transplant leukemia relapse and in patients developing GVHD. Using experimental conditions in which neither donor T cells nor TNFR2-blocking antibody per se have any effect on tumor relapse, we observed that the coadministration of a suboptimal number of T cells and an anti-TNFR2 treatment can trigger alloreactivity and subsequently induce a significant antitumor effect. This was associated with a reduced percentage of activated CD4 These results highlight TNFR2 as a new target molecule for the development of immunotherapies to treat blood malignancy relapse, used either directly in grafted patients or to enhance donor lymphocyte infusion strategies. More widely, they open the door for new perspectives to amplify antitumor responses against solid cancers by directly targeting Tregs through their TNFR2 expression.
Sections du résumé
BACKGROUND
Targeting immune checkpoints that inhibit antitumor immune responses has emerged as a powerful new approach to treat cancer. We recently showed that blocking the tumor necrosis factor receptor-type 2 (TNFR2) pathway induces the complete loss of the protective function of regulatory T cells (Tregs) in a model of graft-versus-host disease (GVHD) prevention that relies on Treg-based cell therapy. Here, we tested the possibility of amplifying the antitumor response by targeting TNFR2 in a model of tumor relapse following hematopoietic stem-cell transplantation, a clinical situation for which the need for efficient therapeutic options is still unmet.
METHOD
We developed appropriate experimental conditions that mimic patients that relapsed from their initial hematological malignancy after hematopoietic stem-cell transplantation. This consisted of defining in allogeneic bone marrow transplantation models developed in mice, the maximum number of required tumor cells and T cells to infuse into recipient mice to develop a model of tumor relapse without inducing GVHD. We next evaluated whether anti-TNFR2 treatment could trigger alloreactivity and consequently antitumor immune response. In parallel, we also studied the differential expression of TNFR2 on T cells including Treg from patients in post-transplant leukemia relapse and in patients developing GVHD.
RESULTS
Using experimental conditions in which neither donor T cells nor TNFR2-blocking antibody per se have any effect on tumor relapse, we observed that the coadministration of a suboptimal number of T cells and an anti-TNFR2 treatment can trigger alloreactivity and subsequently induce a significant antitumor effect. This was associated with a reduced percentage of activated CD4
CONCLUSIONS
These results highlight TNFR2 as a new target molecule for the development of immunotherapies to treat blood malignancy relapse, used either directly in grafted patients or to enhance donor lymphocyte infusion strategies. More widely, they open the door for new perspectives to amplify antitumor responses against solid cancers by directly targeting Tregs through their TNFR2 expression.
Identifiants
pubmed: 35387779
pii: jitc-2021-003508
doi: 10.1136/jitc-2021-003508
pmc: PMC8987798
pii:
doi:
Substances chimiques
Receptors, Tumor Necrosis Factor, Type II
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No, there are no competing interests.
Références
J Immunol Res Ther. 2016;1(1):1-14
pubmed: 27722210
Blood. 2017 Jul 13;130(2):221-228
pubmed: 28468799
J Immunol. 2006 Jan 15;176(2):1026-35
pubmed: 16393990
J Exp Med. 2002 Aug 5;196(3):389-99
pubmed: 12163567
J Exp Med. 2004 Aug 2;200(3):277-85
pubmed: 15280421
Blood. 2009 Jan 1;113(1):85-94
pubmed: 18812472
J Clin Invest. 2003 Dec;112(11):1688-96
pubmed: 14660744
Front Cell Dev Biol. 2020 Dec 04;8:596831
pubmed: 33344453
J Immunol. 2006 Jan 15;176(2):1266-73
pubmed: 16394018
Blood. 2021 Jun 10;137(23):3212-3217
pubmed: 33720354
Gastroenterology. 2015 Oct;149(4):993-1005.e2
pubmed: 26072395
Blood. 2011 Jan 20;117(3):1061-70
pubmed: 20952687
Sci Transl Med. 2013 Jan 16;5(168):168ra9
pubmed: 23325802
J Immunol. 2012 Jul 1;189(1):464-74
pubmed: 22649199
Oncotarget. 2018 Nov 2;9(86):35611-35622
pubmed: 30479692
Cell. 2007 Apr 6;129(1):33-6
pubmed: 17418783
J Immunol Res. 2018 Aug 5;2018:3758713
pubmed: 30155493
Blood Adv. 2021 Mar 9;5(5):1425-1436
pubmed: 33666654
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21666-21672
pubmed: 31597740
Nat Rev Drug Discov. 2010 Jun;9(6):482-93
pubmed: 20489699
Cancer Res. 2007 Jun 15;67(12):5929-39
pubmed: 17575163
J Leukoc Biol. 2003 Oct;74(4):572-82
pubmed: 12960285
Blood. 2016 Feb 25;127(8):1044-51
pubmed: 26563133
Sci Transl Med. 2019 Oct 2;11(512):
pubmed: 31578241
J Immunol. 2013 Feb 1;190(3):1076-84
pubmed: 23277487
PLoS One. 2013 Nov 14;8(11):e80063
pubmed: 24244610
Biol Blood Marrow Transplant. 2019 Jan;25(1):94-99
pubmed: 30195074
Sci Signal. 2017 Jan 17;10(462):
pubmed: 28096513
Haematologica. 2012 Nov;97(11):1678-85
pubmed: 22581007
Blood. 2014 Jul 24;124(4):638-44
pubmed: 24923299
J Leukoc Biol. 2020 Jun;107(6):971-980
pubmed: 32202358
Biol Blood Marrow Transplant. 2018 Sep;24(9):1788-1794
pubmed: 29751114
Cell Immunol. 2009;254(2):149-54
pubmed: 18835598
Leukemia. 2014 Dec;28(12):2406-10
pubmed: 25102947
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Nat Med. 2016 Jan;22(1):16-7
pubmed: 26735402
Leukemia. 2019 May;33(5):1206-1218
pubmed: 30356161
J Clin Invest. 2010 Dec;120(12):4190-2
pubmed: 21099102
Eur J Immunol. 2011 Feb;41(2):335-44
pubmed: 21268004
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Cell Commun Signal. 2020 Jun 16;18(1):94
pubmed: 32546175
J Leukoc Biol. 2020 Jun;107(6):981-991
pubmed: 32449229
J Exp Med. 2002 Aug 5;196(3):401-6
pubmed: 12163568
J Immunol. 2004 Oct 1;173(7):4500-9
pubmed: 15383581
J Clin Invest. 2012 Nov;122(11):4094-104
pubmed: 23064360
Sci Transl Med. 2010 Jul 21;2(41):41ra52
pubmed: 20650872
J Exp Med. 2016 Aug 22;213(9):1881-900
pubmed: 27526711
J Immunol. 2014 Feb 1;192(3):1320-31
pubmed: 24379122
Front Immunol. 2018 Jan 22;9:10
pubmed: 29403494
J Clin Invest. 2010 Dec;120(12):4558-68
pubmed: 21099113
N Engl J Med. 2016 Jul 14;375(2):143-53
pubmed: 27410923
Blood. 2002 May 15;99(10):3493-9
pubmed: 11986199
Blood. 2011 Apr 7;117(14):3921-8
pubmed: 21292771
Oncoimmunology. 2015 Apr 02;4(3):e990800
pubmed: 25949908
Blood. 2016 Sep 22;128(12):1651-9
pubmed: 27506541